Emavusertib for recurrent brain lymphoma after prior treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1/2 trial tests emavusertib (a targeted medicine) in adults with primary central nervous system lymphoma that has come back or not responded to treatment. It’s designed to find safe dosing and see how well the treatment can control the lymphoma in the brain/spinal fluid.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Have enough health to live at least 3 months
- Have primary central nervous system lymphoma confirmed by pathology or typical scans (brain biopsy usually not required)
- If the lymphoma is in the brain tissue, there must be clear signs it is actively progressing on a recent brain MRI/CT (usually with a measurable lesion)
- If the lymphoma is only in the fluid spaces (leptomeningeal), a spinal fluid test must show abnormal lymphoma cells recently
- You cannot have certain other cancers or lymphoma in the body (they check this with a PET or CT scan of chest/abdomen/pelvis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, epcoritamab and ibrutinib, for people whose lymphoma has come back or not responded to treatment and has spread to the brain or spinal cord. The goal is to see if this combination can help control the disease.
This trial combines an experimental drug, emavusertib, with zanubrutinib (a standard targeted therapy) for people with chronic lymphocytic leukemia (CLL) or other B-cell cancers. It aims to see if the combination can improve response in patients who still have some disease despite taking zanubrutinib or whose disease has worsened on it.
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
This trial studies camrelizumab (an immune medicine) for primary CNS lymphoma that has come back after standard treatment. It aims to shrink the lymphoma seen on MRI and help control the disease with a new immune-based approach.
This Phase 2 trial tests a combination medicine (orelabrutinib with pemetrexed) to treat lymphoma that has returned or is not responding, specifically in the brain or spinal fluid. If you qualify, the goal is to shrink measurable tumors and improve control of central nervous system lymphoma.
This Phase 2 trial studies a combination of anti-cancer medicines to treat lymphoma that is only in the brain/spinal fluid (central nervous system, or CNS), especially when it has come back or not responded. If you qualify, you may benefit from improved tumor control and possibly better symptom control.
Hear when a new Relapsed Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.